4-(2-Amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid | 857760-67-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-Amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid
• CAS: 857760-67-9
• 化学式: C₁₀H₉NO₅
• 分子量: 223.18
• InChiKey: YCJNYHCCOXVYAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• COMPOSITION COMPRISING INTERFERON GAMMA AND AN HDAC INHIBITOR OR GONADOTROPIN RECEPTOR SIGNALLING HORMONE
  申请人：Idogen AB

  公开号：EP3238726A2

  公开（公告）日：2017-11-01

  The invention relates to the use of a composition comprising at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein said inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.

  本发明涉及一种包含至少两种化合物（每种化合物都能诱导吲哚胺-2,3-二氧 化酶）的组合物，用于治疗自身免疫紊乱或疾病或移植或基因治疗修饰细胞的免疫排斥反应，其中所述诱导剂具有不同的作用机制，并且该组合物对 IDO 水平具有协同作用。
• THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS
  申请人：Idogen AB

  公开号：EP2164500A1

  公开（公告）日：2010-03-24
• A COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3-DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR SUFFERING FROM IMMUNE REJECTION OF ORGANS
  申请人：Idogen AB

  公开号：EP2654758A1

  公开（公告）日：2013-10-30
• A COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3-DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR IMMUNE REJECTION OF ORGANS
  申请人：Idogen AB

  公开号：EP2654758B1

  公开（公告）日：2017-04-19
• Metabolomics-Based Identification of Disease-Causing Agents
  申请人：Skolnick Jeffrey

  公开号：US20110246081A1

  公开（公告）日：2011-10-06

  A method, computer-readable medium, and system for identifying one or more metabolites associated with a disease, comprising: comparing gene expression data from diseased cells to gene expression data from control cells in order to deduce genes that are differentially-regulated in the diseased cells relative to the control cells; based on enzyme function and pathway data for all human metabolites that utilize the genes that are differentially-regulated in the disease cells, identifying one or more metabolites whose intracellular levels are higher or lower in diseased cells than in control cells, and thereby associating the one or more metabolites with the disease.